Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Targeted lentiviral vector (LVV) engineering enables selective delivery of genetic payloads to defined immune-cell populations, providing an important strategy for in vivo CAR-T cell development. Unlike broadly tropic VSV-G-pseudotyped LVVs, targeted LVVs are engineered to preferentially recognize selected cell-surface receptors while reducing non-target cell transduction.
We provide integrated targeted LVV engineering support spanning target selection, targeting ligand design, envelope and fusogen engineering, vector architecture optimization, and targeting performance evaluation. Targeting strategies can be tailored to specific immune-cell populations, including T-cell subsets, using receptor-directed binders and engineered viral envelopes. Candidate vectors can then be evaluated for targeting specificity, transduction efficiency, selectivity, and functional CAR expression to support the identification of LVV candidates for downstream in vivo evaluation.
Targeted LVV development requires coordinated optimization across the entire delivery system:
Target Recognition
Selective Entry
CAR Delivery
Functional Expression
Targeting Validation
We integrate these engineering steps rather than optimizing individual components in isolation. Target receptor characteristics guide ligand selection, ligand configuration informs envelope engineering, and the resulting targeting system is evaluated together with the CAR vector architecture.
This integrated approach enables systematic identification of limiting factors and supports iterative refinement of targeted LVV candidates.
Target receptor selection establishes the basis for cell-selective LVV delivery. We assess receptor expression, accessibility, and distribution across target and non-target cell populations to determine whether a receptor is suitable for targeted vector development.
We then select or engineer an appropriate receptor-binding ligand and optimize its configuration for incorporation into the LVV targeting system.
Engineering Focus
Target Receptor Assessment
Expression • Accessibility • Target/Non-Target Distribution • Receptor Suitability
Potential Targeting Modalities
scFv • VHH/Nanobody • DARPin • Fab • Other receptor-binding ligands
Targeting Configuration
Binding Affinity • Ligand Orientation • Display Configuration • Receptor Accessibility
The envelope is a central determinant of LVV tropism and cell entry. For targeted delivery, we engineer the envelope system to reduce undesired native receptor interactions while introducing mechanisms for preferential recognition and entry into the intended cell population.
Our approach can incorporate native receptor detargeting, targeting ligand display, envelope/fusogen selection, and fusion optimization according to the target receptor and vector design.
Engineering Focus
Targeted Entry Strategy
01 Reduce Native Entry:
Minimize undesired envelope-mediated transduction of non-target cells.
02 Introduce Receptor-Specific Recognition:
Incorporate and optimize a targeting ligand for the intended cell-surface receptor.
03 Maintain Productive Fusion Activity:
Preserve efficient membrane fusion, vector integrity, and functional titer.
04 Evaluate Target-Cell Selectivity:
Compare transduction and CAR expression in target-positive and non-target cell models.
Envelope engineering is performed together with ligand and vector architecture optimization to establish a targeted LVV configuration suitable for subsequent functional evaluation.
Selective entry alone is insufficient for effective in vivo CAR-T generation. The vector genome must also support appropriate CAR expression while maintaining overall vector performance.
We optimize the CAR expression cassette and regulatory architecture in parallel with the targeting system, considering promoter selection, regulatory elements, payload configuration, and strategies for controlling unwanted expression.
Key Optimization Areas
Targeted LVV candidates are evaluated using comparative models to determine whether delivery is preferentially associated with the intended receptor and target-cell population.
Target-positive and target-negative cells are assessed in parallel, with receptor-blocking, receptor-deficient, or other mechanistic controls incorporated where appropriate.
Targeting Efficiency
Targeting Specificity
Receptor Dependence
Vector Performance
Functional Activity
The resulting data are used to determine whether targeting performance is primarily limited by ligand recognition, envelope-mediated entry, vector architecture, or downstream CAR expression, enabling focused optimization rather than trial-and-error engineering.
Targeted LVV engineering can support a range of research programs requiring selective genetic modification of immune cells, including:
T-Cell Subset Engineering
selective delivery to defined T-cell populations such as CD4+ or CD8+ cells.
Targeted Immune-Cell Engineering
vector development for other defined immune-cell populations or receptors.
Cell-Specific Gene Delivery
targeted delivery of research payloads where selective cellular entry is required.
Targeted LVV Candidate Development
engineering and comparative evaluation of vector candidates for downstream preclinical studies.
In Vivo CAR-T Development
targeted delivery of CAR constructs for direct generation of
We design the vector around the intended target-cell population and receptor rather than applying a one-size-fits-all pseudotyping strategy.
Targeting ligands, receptor detargeting, envelope selection, and fusogenic performance are considered as interconnected engineering parameters.
Target-positive and target-negative cell systems can be incorporated to evaluate selectivity, transduction efficiency, and receptor-dependent delivery.
Vector design and characterization are aligned with the requirements of downstream in vivo CAR-T studies, providing a bridge from vector engineering to translational evaluation.
Targeting modality, envelope platform, payload architecture, and analytical strategy can be adapted to the biological characteristics and development stage of each project.
From target selection and envelope engineering to functional vector characterization, we provide an integrated approach for developing selective, application-oriented lentiviral vectors for in vivo CAR-T research.
Discuss Your Targeted LVV Project
Copyright © 2026 Creative Biogene. All rights reserved.